financetom
Business
financetom
/
Business
/
Lachlan Murdoch, Michael Dell, Ellison involved in TikTok deal, Trump says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lachlan Murdoch, Michael Dell, Ellison involved in TikTok deal, Trump says
Sep 21, 2025 11:44 AM

WASHINGTON, Sept 21 (Reuters) - President Donald Trump

said on Sunday that business leaders Lachlan Murdoch, Larry

Ellison and Michael Dell would be involved as U.S. investors in

a proposed deal to keep TikTok operating in the United States.

Trump has said the U.S. and China have made progress on a deal

requiring TikTok's American assets to be transferred to U.S.

owners from China's ByteDance.

Murdoch, the CEO of Fox Corp, recently cemented long-term

control of his family's media empire that includes Fox News and

the Wall Street Journal after settling a years-long legal battle

with his siblings. The family patriarch, 94-year-old Rupert

Murdoch, may also be involved in the deal, Trump said.

Ellison, the co-founder of Oracle and a major Republican donor,

has long been linked to a potential TikTok deal. Dell is the CEO

of Dell Technologies ( DELL ).

Trump praised the group in an interview with Fox News' "The

Sunday Briefing" program, calling them prominent people and

"American patriots."

"I think they're going to do a really good job," Trump said,

crediting TikTok with helping build his support among young

voters in the 2024 presidential election.

The Trump administration has declined to enforce a U.S. law

enacted during the Biden administration requiring TikTok's

divestiture over fears that its U.S. user data could be accessed

by the Chinese government. Trump has included negotiations over

the popular social media app, which counts 170 million U.S.

users, as part of wide-ranging economic talks with China.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Thyssenkrupp must commit to $3.3 bln green steel project, Habeck says
Thyssenkrupp must commit to $3.3 bln green steel project, Habeck says
Sep 16, 2024
HERNE, Germany, Sept 16 (Reuters) - Germany's Thyssenkrupp must demonstrate its commitment to a planned 3 billion euro ($3.3 billion) green steel site, the country's Economy Minister Robert Habeck said, days after the company flagged the project's cost may increase. It is very important that Thyssenkrupp clearly underlines that it wants to stick with the project, Habeck told Reuters on...
Korro Bio Partners With Novo Nordisk to Develop Genetic Medicines
Korro Bio Partners With Novo Nordisk to Develop Genetic Medicines
Sep 16, 2024
09:09 AM EDT, 09/16/2024 (MT Newswires) -- Korro Bio ( KRRO ) said Monday it has partnered with Novo Nordisk (NVO) to discover and develop new genetic medicines, with an initial focus on cardiometabolic disease treatments. Under terms of the partnership, Korro will receive $530 million in upfront, development and commercial milestone payments, in addition to tiered royalties and research...
Guardian Pharmacy Services Launches IPO
Guardian Pharmacy Services Launches IPO
Sep 16, 2024
01:41 PM EDT, 09/16/2024 (MT Newswires) -- Guardian Pharmacy Services said Monday it has launched its underwritten initial public offering of 6.75 million class A common shares. The company said it expects to grant the underwriters a 30-day option to buy up to about 1 million additional shares at the IPO price, less the underwriting discount. The estimated IPO price...
FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers
FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers
Sep 16, 2024
Monday, the FDA lifted the partial clinical hold on studies of Zentalis Pharmaceuticals, Inc.’s azenosertib, the company’s novel, selective, and orally bioavailable inhibitor of WEE1. The FDA has cleared the company to resume enrollment in all ongoing azenosertib clinical studies with no changes in the clinical development plan. Zentalis will be working with clinical trial investigators to resume study activities...
Copyright 2023-2026 - www.financetom.com All Rights Reserved